114 related articles for article (PubMed ID: 18379032)
1. [Cancer immunotherapy using gammadelta T cells ex vivo expanded by bisphosphonate].
Kimura S
Clin Calcium; 2008 Apr; 18(4):499-505. PubMed ID: 18379032
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy.
Sato K; Kimura S; Segawa H; Yokota A; Matsumoto S; Kuroda J; Nogawa M; Yuasa T; Kiyono Y; Wada H; Maekawa T
Int J Cancer; 2005 Aug; 116(1):94-9. PubMed ID: 15756684
[TBL] [Abstract][Full Text] [Related]
3. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
4. Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: A new approach.
Dokouhaki P; Han M; Joe B; Li M; Johnston MR; Tsao MS; Zhang L
Cancer Lett; 2010 Nov; 297(1):126-36. PubMed ID: 20537791
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of gammadelta T cells reactive against cytomegalovirus-infected cells in a mouse xenograft tumor model.
Devaud C; Bilhere E; Loizon S; Pitard V; Behr C; Moreau JF; Dechanet-Merville J; Capone M
Cancer Res; 2009 May; 69(9):3971-8. PubMed ID: 19383918
[TBL] [Abstract][Full Text] [Related]
6. Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates.
Sanders JM; Ghosh S; Chan JM; Meints G; Wang H; Raker AM; Song Y; Colantino A; Burzynska A; Kafarski P; Morita CT; Oldfield E
J Med Chem; 2004 Jan; 47(2):375-84. PubMed ID: 14711309
[TBL] [Abstract][Full Text] [Related]
7. Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells.
Muraro M; Mereuta OM; Carraro F; Madon E; Fagioli F
Cell Immunol; 2007 Oct; 249(2):63-72. PubMed ID: 18163982
[TBL] [Abstract][Full Text] [Related]
8. Harnessing γδ T cells in anticancer immunotherapy.
Hannani D; Ma Y; Yamazaki T; Déchanet-Merville J; Kroemer G; Zitvogel L
Trends Immunol; 2012 May; 33(5):199-206. PubMed ID: 22364810
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity and some immunological properties of gammadelta T-cells from patients with gastrointestinal carcinomas.
Murayama M; Tanaka Y; Yagi J; Uchiyama T; Ogawa K
Anticancer Res; 2008; 28(5B):2921-31. PubMed ID: 19031935
[TBL] [Abstract][Full Text] [Related]
10. Pitfalls on the roadmap to gammadelta T cell-based cancer immunotherapies.
Martinet L; Poupot R; Fournié JJ
Immunol Lett; 2009 May; 124(1):1-8. PubMed ID: 19465238
[TBL] [Abstract][Full Text] [Related]
11. Nano-technology based carriers for nitrogen-containing bisphosphonates delivery as sensitisers of γδ T cells for anticancer immunotherapy.
Hodgins NO; Wang JT; Al-Jamal KT
Adv Drug Deliv Rev; 2017 May; 114():143-160. PubMed ID: 28694026
[TBL] [Abstract][Full Text] [Related]
12. The therapeutic potential of immuno-cell therapy of cancer in combination with aminobisphosphonates.
Goto S; Noguchi A; Jinguji H; Takahara M
Anticancer Res; 2006; 26(6A):3989-95. PubMed ID: 17195447
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocytes-mediated activation mechanism.
Simoni D; Gebbia N; Invidiata FP; Eleopra M; Marchetti P; Rondanin R; Baruchello R; Provera S; Marchioro C; Tolomeo M; Marinelli L; Limongelli V; Novellino E; Kwaasi A; Dunford J; Buccheri S; Caccamo N; Dieli F
J Med Chem; 2008 Nov; 51(21):6800-7. PubMed ID: 18937434
[TBL] [Abstract][Full Text] [Related]
14. Defective gammadelta T-cell function and granzyme B gene polymorphism in a cohort of newly diagnosed breast cancer patients.
Gaafar A; Aljurf MD; Al-Sulaiman A; Iqniebi A; Manogaran PS; Mohamed GE; Al-Sayed A; Alzahrani H; Alsharif F; Mohareb F; Ajarim D; Tabakhi A; Al-Hussein K
Exp Hematol; 2009 Jul; 37(7):838-48. PubMed ID: 19446661
[TBL] [Abstract][Full Text] [Related]
15. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes.
Todaro M; D'Asaro M; Caccamo N; Iovino F; Francipane MG; Meraviglia S; Orlando V; La Mendola C; Gulotta G; Salerno A; Dieli F; Stassi G
J Immunol; 2009 Jun; 182(11):7287-96. PubMed ID: 19454726
[TBL] [Abstract][Full Text] [Related]
16. IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy.
Thedrez A; Harly C; Morice A; Salot S; Bonneville M; Scotet E
J Immunol; 2009 Mar; 182(6):3423-31. PubMed ID: 19265120
[TBL] [Abstract][Full Text] [Related]
17. Strategies to Improve the Antitumor Effect of γδ T Cell Immunotherapy for Clinical Application.
Miyashita M; Shimizu T; Ashihara E; Ukimura O
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445615
[TBL] [Abstract][Full Text] [Related]
18. Cancer immunotherapy harnessing γδ T cells and programmed death-1.
Tanaka Y
Immunol Rev; 2020 Nov; 298(1):237-253. PubMed ID: 32888218
[TBL] [Abstract][Full Text] [Related]
19. Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer.
Nagamine I; Yamaguchi Y; Ohara M; Ikeda T; Okada M
Hiroshima J Med Sci; 2009 Mar; 58(1):37-44. PubMed ID: 19400555
[TBL] [Abstract][Full Text] [Related]
20. Aminobisphosphonates as new weapons for gammadelta T Cell-based immunotherapy of cancer.
Caccamo N; Meraviglia S; Cicero G; Gulotta G; Moschella F; Cordova A; Gulotta E; Salerno A; Dieli F
Curr Med Chem; 2008; 15(12):1147-53. PubMed ID: 18473809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
